Screener
Ligand Pharmaceuticals LGND Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| June 30, 2026 | Amortized cost | Gross unrealized gains | Gross unrealized losses | Estimated fair value |
|---|---|---|---|---|
| Corporate notes/bonds | 52,307 | — | (130) | 52,177 |
| Corporate equity securities | 20,850 | 63,477 | (3,314) | 81,013 |
| Commercial paper | 7,430 | — | (6) | 7,424 |
| Total short-term investments | $291,586 | $63,477 | $(4,007) | $351,056 |
| December 31, 2025 | ||||
| U.S. Government Agencies | $175,780 | $89 | $(38) | $175,831 |
| Corporate notes/bonds | 124,249 | 98 | (52) | 124,295 |
| U.S. Treasuries | 113,055 | 137 | (4) | 113,188 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's cash, cash equivalents, and marketable securities?
- Ligand Pharmaceuticals (LGND) reported cash, cash equivalents, and marketable securities of $351.06M in Q2 2026.
- How has Ligand Pharmaceuticals's cash, cash equivalents, and marketable securities changed year-over-year?
- Ligand Pharmaceuticals's cash, cash equivalents, and marketable securities increased by 132.7% year-over-year, from $150.85M to $351.06M.
- What is the long-term trend for Ligand Pharmaceuticals's cash, cash equivalents, and marketable securities?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's cash, cash equivalents, and marketable securities has grown at a 11.5% compound annual growth rate (CAGR), from $324.48M to $558.59M.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.
Ask your AI about Ligand Pharmaceuticals's cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude